ReviewCancer science2018
Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.
Review in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- B-cell and plasma cell proliferations associated with T follicular helper cell lymphomas: clinical-pathological and genetic features.Virchows Archiv : an international journal of pathology · 2026Article
- Multi-omics analysis identifies GAA as an independent poor prognostic biomarker and candidate therapeutic target in angioimmunoblastic T-cell lymphoma.Frontiers in immunology · 2026Article
- Insights into Nodal T-Follicular Helper Cell lymphomas and Peripheral T-Cell Lymphomas, Not Otherwise Specified, in Slovenian Patients: Mutational Landscape, Clinicopathological Characteristics, and Outcomes.Annals of hematology · 2025Article
- The Role of Epigenetic Modifier Mutations in Peripheral T-Cell Lymphomas.Current issues in molecular biology · 2023Review
- Article
- [Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
- TheCancers · 2023Article
- DNMT3AOncogene · 2023Article
- Deciphering the spectrum of cutaneous lymphomas expressing TFH markers.Scientific reports · 2023Article
- Metabolic determinants of tumour initiation.Nature reviews. Endocrinology · 2023Review
- Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL).Frontiers in oncology · 2023Review
- Article
- Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.Diagnostics (Basel, Switzerland) · 2022Review
- Review
- A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.Frontiers in oncology · 2022Article
- Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma.Current oncology (Toronto, Ont.) · 2021Review
- How I Diagnose Angioimmunoblastic T-Cell Lymphoma.American journal of clinical pathology · 2021Review
- Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas.Experimental hematology & oncology · 2021Article
- Targeted based therapy in nodal T-cell lymphomas.Leukemia · 2021Review
- Update on recurrent mutations in angioimmunoblastic T-cell lymphoma.International journal of clinical and experimental pathology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is an age-related malignant lymphoma, characterized by immune system-dysregulated symptoms. Recent sequencing studies have clarified the recurrent mutations in ras homology family member A (RHOA) and in genes encoding epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2), DNA methyl transferase 3 alpha (DNMT3A) and isocitrate dehydrogenase 2, mitochondrial (IDH2), as well as those related to the T-cell receptor signaling pathway in AITL. In this review, we focus on how this genetic information has changed the understanding of the developmental process of AITL and will in future lead to individualized therapies for AITL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.